{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-24-000009","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.165633+00:00","generated_at":"2026-06-04T23:07:17.302441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash","bullets":["Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.","Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.","Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.","GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.","R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-24-000009","json":"https://secwatch.observer/filing/0001701541-24-000009.json","markdown":"https://secwatch.observer/filing/0001701541-24-000009.md","text":"https://secwatch.observer/filing/0001701541-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/bdtx-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:07:17.302441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4de583e8eb68848cf34c1af76e0489bb00f26334","claim":"Black Diamond Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $82.4 million.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $82.4 million compared to $91.2 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023 was $82.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5f34fb22c8aafbf58e1db5d457832978f178d7a7","claim":"Black Diamond Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $19.4 million.","evidence_excerpt":"Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154124000009/0001701541-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $19.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}